Zoetis Inc. (NYSE:ZTS) Shares Acquired by Nations Financial Group Inc. IA ADV

Nations Financial Group Inc. IA ADV grew its position in Zoetis Inc. (NYSE:ZTS) by 3.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,554 shares of the company’s stock after buying an additional 411 shares during the quarter. Nations Financial Group Inc. IA ADV’s holdings in Zoetis were worth $2,046,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. Cherry Creek Investment Advisors Inc. grew its stake in shares of Zoetis by 2.0% in the third quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock valued at $590,000 after buying an additional 58 shares in the last quarter. Hancock Whitney Corp grew its stake in Zoetis by 0.3% during the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock worth $3,628,000 after purchasing an additional 61 shares in the last quarter. Strategy Asset Managers LLC grew its stake in Zoetis by 3.5% during the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after purchasing an additional 62 shares in the last quarter. Procyon Advisors LLC grew its stake in Zoetis by 1.4% during the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after purchasing an additional 63 shares in the last quarter. Finally, Aberdeen Wealth Management LLC grew its stake in Zoetis by 1.9% during the 3rd quarter. Aberdeen Wealth Management LLC now owns 3,566 shares of the company’s stock worth $697,000 after purchasing an additional 68 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Down 4.5 %

Zoetis stock opened at $157.54 on Friday. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The company has a market capitalization of $71.07 billion, a P/E ratio of 29.61, a PEG ratio of 2.77 and a beta of 0.90. The stock has a 50-day simple moving average of $168.51 and a 200-day simple moving average of $178.81.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Equities research analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.27%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio is presently 36.56%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. UBS Group assumed coverage on Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. Morgan Stanley lowered their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Piper Sandler decreased their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Finally, Stifel Nicolaus decreased their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and a consensus target price of $214.90.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by company insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.